NeoGenomics (NASDAQ: NEO) announced a leadership succession plan under which President and COO Warren Stone will become chief executive officer and join the board effective January 4, 2027. Current CEO Tony Zook will become executive chairman on the same date.
The company expects preliminary, unaudited third-quarter 2026 revenue of approximately $209 million and approximately 28% year-over-year growth in next-generation sequencing revenue. NeoGenomics said it will provide further details, including an expected increase to full-year revenue guidance, on its third-quarter earnings call.
- Warren Stone, 54, has served as NeoGenomics' president and COO and previously held leadership roles at Ortho Clinical Diagnostics and MilliporeSigma/Merck KGaA.
- Tony Zook will remain CEO through January 3, 2027, before becoming executive chairman.
- Board Chair Lynn Tetrault will step down as chair on January 4, 2027 and remain an independent director until the 2027 annual meeting.
- Michael Kelly will become lead independent director effective January 4, 2027.
- The company said its third-quarter results remain preliminary, unaudited and subject to completion and potential final adjustments.
$NEO Insider Trading Activity
$NEO insiders have traded $NEO stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $NEO stock by insiders over the last 6 months:
- GREG D AUNAN (Chief Accounting Officer) sold 20,000 shares for an estimated $321,400
- LYNN A. TETRAULT has made 0 purchases and 2 sales selling 10,614 shares for an estimated $118,823.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NEO Hedge Fund Activity
We have seen 144 institutional investors add shares of $NEO stock to their portfolio, and 97 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST TRUST ADVISORS LP added 3,950,890 shares (+64.1%) to their portfolio in Q2 2026, for an estimated $57,643,485
- D. E. SHAW & CO., INC. removed 3,102,770 shares (-58.6%) from their portfolio in Q2 2026, for an estimated $45,269,414
- FIRST LIGHT ASSET MANAGEMENT, LLC added 2,549,545 shares (+26.2%) to their portfolio in Q2 2026, for an estimated $37,197,861
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 2,391,784 shares (+inf%) to their portfolio in Q2 2026, for an estimated $34,896,128
- PFM HEALTH SCIENCES, LP removed 1,784,552 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $26,036,613
- NOMURA ASSET MANAGEMENT INTERNATIONAL INC. added 1,585,200 shares (+45.9%) to their portfolio in Q2 2026, for an estimated $23,128,068
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,212,407 shares (+inf%) to their portfolio in Q2 2026, for an estimated $17,689,018
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$NEO Congressional Stock Trading
Members of Congress have traded $NEO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NEO stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 08/07.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
